

AMENDMENTS TO THE CLAIMS

1-57 (Cancelled)

58. (Currently Amended) A method for down-regulation of autologous OPGL in an individual in need thereof, the method comprising administering, to the individual, an effective amount of an immunogenic agent capable of inducing an immune response against the subject's autologous OPGL.

59. (Currently Amended) A method for down-regulation of autologous OPGL in an individual in need thereof, the method comprising administering, to the individual, an effective amount of an immunogenic agent capable of inducing an antibody response against the subject's autologous OPGL.

60. (Cancelled)

61. (Currently Amended) A method for treating, ameliorating or preventing disease characterized by excessive bone resorption in a subject in need thereof, the method comprising administering, to the subject, an effective amount of an immunogenic agent capable of inducing an immune response against the subject's autologous OPGL.

62. (Currently Amended) A method for treating, ameliorating or preventing disease characterized by excessive bone resorption in a subject in need thereof, the method comprising administering,

to the subject, an effective amount of an immunogenic agent capable of inducing an antibody response against the subject's autologous OPGL.

63. (Canceled)

64. (Cancelled)

65. (Currently Amended) The method according to any one of claims 58, 59, 61 or -62, wherein the active immunization comprises administration of an immunogenic agent is selected from the group consisting of a polypeptide vaccine, a nucleic acid vaccine, a live vaccine, and a viral vaccine.

66. (Currently Amended) The method according to any one of claims 58, 59, 61 or -62, which further comprises that wherein the immunogenic agent is in admixture with an adjuvant.

67. (New) A method for treating or ameliorating disease characterized by excessive bone resorption comprising administering to a subject at risk or in need thereof an effective amount of an immunogenic agent capable of inducing an immune response against the subject's autologous OPGL.

68. (New) A method for treating or ameliorating disease characterized by excessive bone resorption comprising administering to a subject at risk or in need thereof an effective amount of an

immunogenic agent capable of inducing an antibody response against the subject's autologous OPGL.

69. (New) The method according to any one of claims 67 or 68, wherein the immunogenic agent is selected from the group consisting of a polypeptide vaccine, a nucleic acid vaccine, a live vaccine, and a viral vaccine.

70. (New) The method according to any one of claims 67 or 68, wherein the immunogenic agent is in admixture with an adjuvant.